AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cilia- and flagella-associated protein 74

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9C0B2

UPID:

CFA74_HUMAN

Alternative names:

-

Alternative UPACC:

Q9C0B2; A4VCI2; H7C4E1; Q5T2D9; Q5T2E0; Q69YW0; Q6ZSJ4

Background:

Cilia- and flagella-associated protein 74 plays a crucial role in the movement of cilia and flagella, essential for cell motility and fluid flow across cell surfaces. This protein is integral to the central apparatus of the cilium axoneme, contributing to the precise architecture and function of sperm, as well as respiratory cilia.

Therapeutic significance:

Given its pivotal role in primary ciliary dyskinesia, particularly Ciliary dyskinesia, primary, 49, without situs inversus, understanding the function and mechanisms of Cilia- and flagella-associated protein 74 could pave the way for innovative treatments. Targeting the protein's function may offer new therapeutic avenues for managing respiratory infections and infertility associated with this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.